Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience

Mostrar otras versiones (1)

Background: In November 2020, the U.S. Food and Drug Administration (FDA) issued emergency use authorization (EUA) for monoclonal antibody (mAb) therapy in patients with mild to moderate COVID-19 who are at high risk for disease progression. These mAbs reduce the risk of hospitalization in the gener...

Descripción completa

Detalles Bibliográficos
Autores principales: Amanam, Idoroenyi, Yao, Janny M., Puing, Alfredo, Tsai, Ni-Chun, Samuels, Diana, Ngo, Dat, Ho, Stephanie, Ali, Haris, Aribi, Ahmed, Arslan, Shukaib, Artz, Andrew S., Htut, Myo, Koller, Paul, Salhotra, Amandeep, Sandhu, Karamjeet S., Nikolaenko, Liana, Pawlowska, Anna B, Shouse, Geoffrey, Stein, Anthony S., Marcucci, Guido, Forman, Stephen J, Nakamura, Ryotaro, Dadwal, Sanjeet S, Al Malki, Monzr M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
904.Outcomes Research-Non-Malignant Conditions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701569/
http://dx.doi.org/10.1182/blood-2021-154187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701569/
http://dx.doi.org/10.1182/blood-2021-154187

Ejemplares similares